Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

cyp4v2 gene mutant and its application

A CYP4V2, mutant technology, applied in the application, genetic engineering, plant genetic improvement and other directions, can solve problems that need to be deepened

Inactive Publication Date: 2020-02-21
THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the current research on primary BCD, especially its pathogenic genes, still needs to be in-depth

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • cyp4v2 gene mutant and its application
  • cyp4v2 gene mutant and its application
  • cyp4v2 gene mutant and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Example 1 Determination of pathogenic mutations in primary crystalline retinal degeneration (BCD)

[0064] 1. Sample collection

[0065] In 2010, the inventor collected a case of BCD patient in Chongqing. There were 4 family members of this patient, including 1 patient and 3 normal members. A total of 4 people participated in the research of the present invention, including 1 patient, 3 normal members (father, elder brother and younger brother), and all family members participating in the research of the present invention signed the informed consent. The patient's pedigree figure 2 As shown, where □ indicates a normal male, ■ indicates a male patient, Denotes a deceased normal female, M denotes a mutation, and + denotes a wild type.

[0066] In this family, the patient developed night blindness at the age of 49, and the fundus examination showed typical crystal-like retinal degeneration changes. image 3 A fundus image of this BCD patient is shown. Depend on im...

Embodiment 2

[0077] Example 2: Sanger method sequencing verification

[0078] Primers were designed for the sequence of CYP4V2 gene (exon 1-11), and the related sequence was obtained by PCR amplification, product purification and sequencing. The specific operation is as follows:

[0079] 1. DNA extraction

[0080] Collection of probands in the BCD family ( figure 2 Members represented by middle ■) peripheral blood, using the conventional phenol-chloroform method to extract the genomic DNA in the peripheral blood leukocytes, using a spectrophotometer to measure the concentration and purity of the DNA, and the OD of the genomic DNA of each sample obtained 260 / OD 280 They are all located between 1.7-2.0, the concentration is not less than 200 ng / microliter, and the total amount is not less than 30 micrograms.

[0081] 2. Primer Design

[0082] The PCR reaction primers were designed with reference to the human genome sequence, as shown in Table 1 below:

[0083] Table 1

[0084]

...

Embodiment 3

[0094] Embodiment 3: Sanger method sequencing verification

[0095]The CYP4V2 gene of all family members (including patients and normal people in the family) and 100 normal people outside the family in the BCD patient family described in Example 1 were detected: using the exons of the CYP4V2 gene in Example 2 1. Design the primers, obtain the relevant sequence of the mutation site by PCR amplification, product purification and sequencing, and verify the correlation between the CYP4V2 gene and the mutation and BCD according to whether the sequence determination results belong to the mutant type or the wild type.

[0096] The specific method steps are as follows:

[0097] 1. DNA extraction

[0098] According to the method for extracting DNA described in Example 2, the genomic DNA in the peripheral venous blood of the subject was extracted and prepared respectively for future use.

[0099] 2. PCR reaction

[0100] Using the primers and PCR conditions designed for exon 1 of the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a CYP4V2 gene mutant and an application thereof, and specifically relates to a separate nucleic acid encoding a CYP4V2 mutant, a separate polypeptide, a method for screening a biological sample susceptible to primary crystal-like retinal degeneration, a system for screening a biological sample susceptible to primary crystal-like retinal degeneration and a kit for screening a biological sample susceptible to primary crystal-like retinal degeneration. Compared with SEQ ID No: 1, the separated nucleic acid encoding the CYP4V2 mutant has c.31C>T mutation. By detecting the existence of the new mutant in the biological sample or not, whether the biological sample is susceptible to the primary crystal-like retinal degeneration can be effectively detected.

Description

technical field [0001] The present invention relates to CYP4V2 gene mutant and application thereof. Specifically, the present invention relates to isolated nucleic acids encoding CYP4V2 mutants, isolated polypeptides, methods for screening biological samples susceptible to primary crystalline retinal degeneration, systems for screening biological samples susceptible to primary crystalline retinal degeneration , kits, constructs and recombinant cells for screening biological samples susceptible to primary crystalline retinal degeneration. Background technique [0002] Bietti's crystalline corneoretinal dystrophy (BCD) is a rare hereditary blinding disease with an incidence of about 1 / 24,000 in the world. 4000. BCD patients usually develop at the age of 20-30 and become blind at the age of 40-50. At present, it has become a major eye disease that threatens the visual function and quality of young and middle-aged people around the world. It will seriously affect the quality o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/12C12N15/63C12N5/10C07K14/47C12Q1/6883C12M1/00C12M1/34
Inventor 孟晓红阴正勤徐海伟黎其友金鑫李世迎
Owner THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com